Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, HER3/4 Mutation or KRAS Mutation
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2018
At a glance
- Drugs Neratinib (Primary) ; Everolimus; Palbociclib; Trametinib
- Indications Solid tumours
- Focus Adverse reactions
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 26 Mar 2018 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.
- 31 Oct 2017 Planned End Date changed from 1 Apr 2023 to 1 Oct 2022.